Deutsch A, Chaimovitzch C, Nagauker-Shriker O, Zlotnik M, Shany S, Levy R
Laboratory of Infectious Diseases, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
J Am Soc Nephrol. 1995 Jul;6(1):102-9. doi: 10.1681/ASN.V61102.
The effect of 1 alpha-hydroxyvitamin D3 (1 alpha OHD3) treatment on the superoxide production of phagocytic cells in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) was studied. A 3-day treatment of CAPD patients with 3 micrograms per day of 1 alpha OHD3 (high-dose treatment) significantly increased NADPH oxidase and killing activities in peritoneal macrophages and peripheral blood monocytes (P < 0.001) as compared with low-dose (0.25 microgram/day of 1 alpha OHD3) treatment or nontreatment. The high oxidase activity observed in macrophages and monocytes after the treatment with 1 alpha OHD3, correlated significantly to the increase in the amount of the cytosolic factor p47 of the NADPH oxidase as detected by western blotting analysis. Superoxide production by the peripheral blood neutrophils of these patients only slightly increased with 1 alpha OHD3 treatment, and the amount of p47 was not affected by 1 alpha OHD3 administration. In order to evaluate the significance of the oxidase cytosolic factor in dictating oxidase activity, a reconstitution of NADPH oxidase was conducted by mixing macrophage cytosols and membranes in a cell-free system. The addition of macrophage cytosol from patients on high-dose treatment to macrophage membranes from patients in all of the categories of treatment resulted in significantly higher (P < 0.001) superoxide production as opposed to the macrophage cytosol from nontreated patients. These results suggest that 1,25(OH)2D3 causes an increase in NADPH oxidase activity in the peritoneal macrophages and monocytes of CAPD patients by inducing synthesis and elevating the amount of the cytosolic factor p47.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了1α-羟维生素D3(1αOHD3)治疗对持续非卧床腹膜透析(CAPD)患者吞噬细胞超氧化物产生的影响。与低剂量(每天0.25微克1αOHD3)治疗或不治疗相比,CAPD患者每天3微克1αOHD3的3天治疗(高剂量治疗)显著增加了腹膜巨噬细胞和外周血单核细胞中的NADPH氧化酶和杀伤活性(P<0.001)。用1αOHD3治疗后在巨噬细胞和单核细胞中观察到的高氧化酶活性,与通过蛋白质印迹分析检测到的NADPH氧化酶胞质因子p47量的增加显著相关。这些患者外周血中性粒细胞的超氧化物产生仅随1αOHD3治疗略有增加,并且p47的量不受1αOHD3给药的影响。为了评估氧化酶胞质因子在决定氧化酶活性中的重要性,在无细胞系统中通过混合巨噬细胞胞质溶胶和细胞膜进行了NADPH氧化酶的重组。与未治疗患者的巨噬细胞胞质溶胶相比,将高剂量治疗患者的巨噬细胞胞质溶胶添加到所有治疗类别患者的巨噬细胞膜中导致超氧化物产生显著更高(P<0.001)。这些结果表明,1,25(OH)2D3通过诱导合成并增加胞质因子p47的量,导致CAPD患者腹膜巨噬细胞和单核细胞中NADPH氧化酶活性增加。(摘要截短为250字)